-
April 24, 2013
Novartis posts a 7% rise in first-quarter profit and announced new group CFO.
Full story
-
July 20, 2012
Swiss drug giant Novartis has beaten analyst expectations with a 6% fall in second-quarter earnings to $3.36 billion, or $1.38 a share.
Full story
-
April 26, 2012
The National Institute for Health and Clinical Excellence has published guidance recommending new drugs for the treatment of multiple sclerosis, chronic myeloid leukaemia and hepatitis C for use on the NHS.
Full story
-
April 24, 2012
Novartis' stock slipped this morning after first-quarter results showed a fall in earnings, largely because of generic competition and the temporary closure of a US manufacturing plant.
Full story
-
May 10, 2011
NHS cost regulators are leaning towards barring the use of Bristol-Myers Squibb's Sprycel, Novartis' Tasigna and high-dose Glivec for the treatment of certain patients with chronic myeloid leukaemia (CML).
Full story
-
April 19, 2011
Novartis says that earnings for the first quarter have been impacted by the strong Swiss franc and expenses related to its $51 billion merger with eye specialist Alcon, but sales leapt 16% thanks to the performance of its new drugs
Full story
-
April 12, 2011
Swiss drugmaker Novartis has ditched a late-stage study assessing Tasigna's potential in a rare type of stomach cancer, but would have been somewhat cheered by a new analysis supporting the use of Gilenya in multiple sclerosis.
Full story